SHANGHAI, Sept. 15, 2025 /PRNewswire/ — EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market.

Jay Wang (Left) and Suguru Ominato (Right)Jay Wang (Left) and Suguru Ominato (Right)

This strategic collaboration underscores EverBridge Group’s leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy, further amplifying its international influence.

Simultaneously, the partnership underscores Cosmotec’s best-in-class digital commercialization platform, which accelerates market access for international medical devices and enables targeted engagement with clinical end-users.

"EverBridge Group’s portfolio demonstrates outstanding clinical efficiency and user-friendly design, aligning perfectly with Japanese physicians’ pursuit of advanced therapeutic solutions," stated Suguru Ominato, CEO of Cosmotec. "By integrating M3’s academic platforms with our localized commercialization expertise, we will accelerate the adoption of these devices across the Japanese market."

"Cosmotec’s digital commercialization model delivers both efficiency and accessibility, which aligns perfectly with our vision for equitable healthcare innovation," said Jay Wang, CEO of EverBridge Group. "By navigating Japan’s rigorous technical and regulatory landscape, this partnership not only delivers transformative solutions to patients but also enhances our global R&D synergy. Lowering barriers to advanced care through innovation and ecosystem collaboration remains central to our globalization journey."

About EverBridge Group

EverBridge Group is a leading medical technology group in Asia, committed to providing global customers with cutting-edge, high-quality, and affordable medical technologies. Our rapidly expanding product portfolio covers three major therapeutic areas: peripheral vascular, neuroscience, and oncology. Supported by Six specialized R&D and lean production centers, we offer top-tier OEM/ODM services in areas including balloons, catheters, stents, surface engineering, and active medical devices.

We collaborate extensively with outstanding enterprises worldwide, building a bridge for medical technology innovation between Asia and the rest of the world. Our goal is to offer healthcare professionals and patients globally better treatment options through advanced and accessible solutions.

For more information, please visit the official website: www.everbridgemed.com

Contact: Ann Chen, communications@everbridgemed.com

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

IBM Study: Profit-Driven CMOs See AI as Growth Driver, but Operational Hurdles Slow Them Down

54% of surveyed executives underestimated the operational complexity of translating AI strategies…

Goonies Achieves NT$250,000 in Funding Through ZecZec Campaign with "Brick Coaster," a Product That Reuses Dormant Toy Blocks

SEOUL, South Korea, Dec. 20, 2024 /PRNewswire/ — Everyone has fond memories…

IBM and Red Hat Commit $5 Billion to Redefine the Future of Open Source in the AI Era

Project Lightwell establishes a trusted enterprise clearinghouse for open source software with…